Sfoglia per Autore
Immunotherapy options in metastatic renal cell cancer: Where we are and where we are going
2006-01-01 Passalacqua, R.; Buti, S.; Tomasello, G.; Longarini, R.; Brighenti, M.; Dalla Chiesa, M.
Gefitinib (G) plus Interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
2007-01-01 Tomasello, G; Buti, S; Bosio, G; Stifani, I; Maestrelli, M; Brighenti, M; Porzio, R; Lazzarelli, S; Negri, F; Longarini, R; Passalacqua, R
Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)
2007-01-01 Passalacqua, R; Buzio, C; Buti, S; Labianca, R; Porta, C; Boni, C; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Caminiti, C
7 Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon α-2° as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial
2007-01-01 Chiesa, Md; Passalacqua, R; Michiara, M; Franciosi, V; Di Costanzo, F; Bisagni, G; Camisa, R; Buti, S; Tomasello, G; Cocconi, G; Italian Oncology Group for Clinical, Research.
Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial
2007-01-01 Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Passalacqua, R
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study
2007-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Porzio, R; Lazzarelli, S; Brighenti, M; Passalacqua, R
Bevacizumab plus immunotherapy, with interleukin-2 (IL-2) and interferone-alpha (IFN-alpha), plus chemotherapy (BIC), in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial
2007-01-01 Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Mazza, G; Passalacqua, R
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon α-2a as first-line endocrine treatments in advanced breast cancer: Updated results of a phase II, prospective, randomised multicentre trial
2007-01-01 Chiesa, M. D.; Passalacqua, R.; Michiara, M.; Franciosi, V.; Di Costanzo, F.; Bisagni, G.; Camisa, R.; Buti, S.; Tomasello, G.; Cocconi, G.
Role of Chemotherapy With Gemcitabine Plus 5-fluorouracil and Chemoimmunotherapy in Metastatic Renal Cell Cancer (mRCC)
2007-01-01 Buti, S; Brighenti, M; Bongiovanni, C; Buzio, Carlo; Chiesa, Md; Alberici, F; Passalacqua, R.
Adjuvant low-dose interleukin-2 (IL2) plus interferon-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the italian oncology group for clinical research (GOIRC)
2007-01-01 Passalacqua, R; Buzio, C; Potenzoni, D; Buti, S; Labianca, R; Porta, C; Nastasi, P; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Alberici, F; Bongiovanni, C; Pezzuolo, D; Caminiti, C
Bevacizumab (B) plus immunotherapy and chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial
2007-01-01 Buti, S; Brighenti, M; Dalla Chiesa, M; Simonelli, C; Passalacqua, R
Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
2007-01-01 Longarini, R; Buti, S; Bosio, G; Brighenti, M; Porzio, R; Negri, F; Passalacqua, R
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A phase II study
2007-01-01 Chiesa, Md; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Lazzarelli, S; Brighenti, M; Passalacqua, R
Overexpression of p53 protein predicts complete response to chemoradiation therapy in T2-T4 bladder cancer: Ten years follow up
2007-01-01 Brighenti, M; Naldi, N; Caminiti, C; Potenzoni, D; Fumagalli, M; Crafa, P; Buti, S; Passalacqua, R
Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: A case report
2007-01-01 Buti, S.; Ricco, M.; Chiesa, M. D.; Copercini, B.; Tomasello, G.; Brighenti, M.; Passalacqua, R.
A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer
2007-01-01 Dalla Chiesa, M.; Buti, S.; Tomasello, G.; Negri, F.; Buononato, M.; Brunelli, A.; Lazzarelli, S.; Brighenti, M.; Donati, G.; Passalacqua, R.
Adjuvant low-dose IL2 plus IFNα in operable renal cell carcinoma: a phase III, randomized, multicenter trial
2008-01-01 Vaglio, A; Alberici, F; Buti, S; Porta, C; Dal Canton, A; Potenzoni, D; Passalacqua, R; Caminiti, C; Buzio, C
Dose-finding/phase II trial with a combination of bevacizumab (B) plus immunotherapy plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): A GOIRC multicentre study
2008-01-01 Buti, S; Lazzarelli, S; Simonelli, C; Lleshi, A; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Passalacqua, R
Bevacizumab (B) plus low-doses immunotherapy (IT), plus chemotherapy (CT) (BIC), in metastatic renal cell cancer (mRCC): antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)
2008-01-01 Buti, S; Lazzarelli, S; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Brighenti, M; Passalacqua, R
Correlazione TC-PET nel follow-up di GIST metastatici trattati con terapia antitirosinchinasica (Imatinib)
2008-01-01 Mazza, G; Archiati, E; Voltini, G; Olivetti, L; Buti, S; Passalacqua, R
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile